216 related articles for article (PubMed ID: 26645401)
21. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
22. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
23. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Maseda E; Aguilar L; Gimenez MJ; Gilsanz F
Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
[TBL] [Abstract][Full Text] [Related]
24. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
Armstrong ES; Farrell DJ; Palchak M; Steenbergen JN
Antimicrob Agents Chemother; 2016 Jan; 60(1):666-8. PubMed ID: 26552971
[TBL] [Abstract][Full Text] [Related]
25. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Bassetti M; Righi E
Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527
[TBL] [Abstract][Full Text] [Related]
26. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Gentile I; Maraolo AE; Borgia G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
[No Abstract] [Full Text] [Related]
27. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
Wagenlehner FM; Alidjanov JF
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964
[TBL] [Abstract][Full Text] [Related]
28. [New possibilities in antibacterial treatment of intra-abdominal infections caused by multiresistant microflora].
Dibirov MD; Khachatryan NN; Isaev AI; Karsotyan GS; Alimova EE; Kostyuk EA
Khirurgiia (Mosk); 2019; (12):74-83. PubMed ID: 31825346
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
[TBL] [Abstract][Full Text] [Related]
31. The role of new antibiotics in intra-abdominal infections in the era of multi-resistant bacteria.
Adámková V
Rozhl Chir; 2019; 98(4):145-151. PubMed ID: 31159547
[TBL] [Abstract][Full Text] [Related]
32. New and Emerging Antibiotics for Complicated Intra-Abdominal Infections.
Durand CR; Alsharhan M; Willett KC
Am J Ther; 2017; 24(6):e763-e769. PubMed ID: 26796653
[TBL] [Abstract][Full Text] [Related]
33. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
34. Ceftolozane/tazobactam: place in therapy.
Giacobbe DR; Bassetti M; De Rosa FG; Del Bono V; Grossi PA; Menichetti F; Pea F; Rossolini GM; Tumbarello M; Viale P; Viscoli C;
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):307-320. PubMed ID: 29493397
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Jackson CA; Newland J; Dementieva N; Lonchar J; Su FH; Huntington JA; Bensaci M; Popejoy MW; Johnson MG; De Anda C; Rhee EG; Bruno CJ
Pediatr Infect Dis J; 2023 Jul; 42(7):557-563. PubMed ID: 37000942
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Kauf TL; Prabhu VS; Medic G; Borse RH; Miller B; Gaultney J; Sen SS; Basu A
BMC Infect Dis; 2017 Apr; 17(1):314. PubMed ID: 28454524
[TBL] [Abstract][Full Text] [Related]
37. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
Mikamo H; Monden K; Miyasaka Y; Horiuchi T; Fujimoto G; Fukuhara T; Yoshinari T; Rhee EG; Shizuya T
J Infect Chemother; 2019 Feb; 25(2):111-116. PubMed ID: 30528561
[TBL] [Abstract][Full Text] [Related]
39. The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials.
Cheng IL; Chen YH; Lai CC; Tang HJ
Int J Antimicrob Agents; 2020 Feb; 55(2):105858. PubMed ID: 31786332
[TBL] [Abstract][Full Text] [Related]
40. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]